Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child‐Pugh B cirrhosis

Cancer Medicine(2022)10.1002/cam4.4906Source: DataRank Database

Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child‐Pugh B cirrhosis is a research paper published in Cancer Medicine (2022). On theSindex it has a DataRank of 0. It has been cited 25 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access25 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 2.62)OA: goldTopics (50)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Wei‐Ting Hwang ORCID,Thomas B. Karasic ORCID,Anne Marie McCarthy ORCID,David E. Kaplan ORCID,William J. Chapin ORCID

Live enrichment

PubMed:35652419 PMC:PMC9844625 OpenAlex:https://openalex.org/W4281606106

National Institutes of Health

Grant: T32 CA009679

NIBIB NIH HHS

Grant: T32 EB016652

National Institutes of Health

Grant: 5T32CA009679-18

Cancer Clinical Epidemiology Training Grant

FWCI

2.62

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.1002/cam4.4906

publisherhttps://doi.org/10.1002/cam4.4906

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4906

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/cam4.4906

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35652419

Fields of Study

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and BiomarkersHepatitis B Virus Studies03 medical and health sciences0302 clinical medicine

MeSH Terms

SorafenibNivolumabAntineoplastic AgentsCarcinoma, HepatocellularHumansLiver CirrhosisLiver NeoplasmsNiacinamidePhenylurea CompoundsRetrospective StudiesTreatment Outcome

Keywords

MedicineSorafenibHepatocellular carcinomaNivolumabInternal medicineCirrhosisHazard ratioTolerabilityCohortGastroenterologyProportional hazards modelRetrospective cohort studyDiscontinuationAdverse effectOncologySurgeryCancerConfidence intervalImmunotherapyLiver cirrhosisProportional hazards modelsPropensity ScoreComparative Effectiveness ResearchNiacinamideCarcinoma, HepatocellularPhenylurea CompoundsLiver NeoplasmsNeoplasms. Tumors. Oncology. Including cancer and carcinogensAntineoplastic AgentsRESEARCH ARTICLESTreatment OutcomeHumansRC254-282Retrospective Studies

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being